Yoon replaces 6 ministers ahead of his 3rd year, general election
US deploys fighter jets in S. Korea for air exercise in Singapore
S. Korea's economy grows 0.6% in Q3, unchanged from earlier estimate
S. Korea successfully tests solid-fuel space rocket
Another search targets opposition leader in corruption probe
Generational shift looms in SK leadership
[KH Explains] Why tighter US subsidy rules could boost Chinese firms
Majority of Korean office workers sleep deprived
US rejects NK's 'double standard' claim on Seoul's satellite launch
Province office raided in probe into wife of opposition leader
GC WellBeing to repurpose liver drug as COVID-19 treatmentBy Lim Jeong-yeo
Published : Feb. 26, 2021 - 17:21
This puts the total count of domestic pursuits for COVID-19 treatments at 14 and vaccines at eight.
Among them, Celltrion’s monoclonal antibody regdanvimab is the only one to have been emergency-approved.
Laennec is made from human placenta. Having been approved in Korea in 2005, the drug has been in use for 16 years as a subcutaneous and intramuscular injection to enhance liver functions in both alcoholic and non-alcoholic fatty liver patients.
For COVID-19, Laennec will be clinically tested as an intravenous injection.
The Drug Ministry said that in animal trials, Laennec showed antiviral effects against COVID-19 such as a reduction in viral load and diminished structural changes in host cells caused by viral invasion.
Laennec is owned by Japan Bio Products. In Korea, GC WellBeing is responsible for both manufacturing and marketing of Laennec.
By Lim Jeong-yeo (email@example.com)
Korea unveils plan to tackle ailing mental health
[KH Explains] China ups OLED ante to take over Korean shares
6 outgoing ministers ‘strong candidates’ for general elections: ruling party